Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Leica Biosystems Acquires Kreatech Diagnostics

July 8, 2013

NEWCASTLE-UPON-TYNE, England and AMSTERDAM, July 8, 2013 /PRNewswire/ –

Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held
provider of DNA fluorescent in-situ hybridization (FISH) probes and target labeling
reagents for microarrays.

“We are very pleased with the acquisition of Kreatech, its extensive portfolio and
development expertise. This will allow Leica Biosystems to better serve our cytogenetics
and anatomic pathology customers. It will also enable us to actively support the future
development of personalized medicine by research and drug development companies” said
Matthias G. Weber, MD, President of Leica Biosystems. “By standardizing and supporting the
interpretation of results with our Aperio ePathologytm imaging solutions, we will provide
our customers with the ability to effectively and efficiently manage ever more complex
diagnostic requirements.”

Kreatech will join Leica Biosystems’ Advanced Staining Business Unit based in
Newcastle-upon-Tyne, UK. The combined business will develop targeted biomarker menus for
Leica’s instrument platforms. Leica Biosystems provides the ThermoBrite(R), and BOND(TM)
systems that are widely used to label tissue specimens for diagnostic interpretation in
cytogenetics and pathology laboratories globally.

“Leica Biosystems is a very natural fit to take Kreatech to the next stage” commented
Kees Moonen, CEO of Kreatech Diagnostics. “Leica will bring global brand recognition,
worldwide commercial reach, extensive cytogenetics and histology portfolios, and the
automation of diagnostic tests on well-established systems. This will tremendously
increase the number of customers that can benefit from Kreatech’s superior solutions.”

About Leica Biosystems

Leica Biosystems is a global leader in workflow solutions and automation, striving to
advance cancer diagnostics to improve lives. Leica Biosystems provides anatomical
pathology laboratories and researchers a comprehensive product range for each step in the
pathology process, from sample preparation and staining to imaging and reporting. Leica’s
easy-to-use and consistently reliable offerings help improve workflow efficiency and
diagnostic confidence. The company is represented in over 100 countries. It has
manufacturing facilities in 6 countries, sales and service organizations in 19 countries,
and an international network of dealers. The company is headquartered in Nussloch,
Germany. Further information can be found at http://www.LeicaBiosystems.com

About Kreatech Diagnostics

Kreatech is a molecular diagnostics company focusing on the development and
commercialization of innovative detection products. Kreatech’s product portfolio enables
customers to detect genetic aberrations that may lead to cancer or other diseases.
Kreatech offers a broad commercial portfolio of REPEAT-FREE(TM) DNA-FISH probes and a
dedicated portfolio for microarray labeling applications using its proprietary
non-enzymatic Universal Linkage System (ULS(TM)) labeling technology. Further information
can be found at http://www.Kreatech.com

SOURCE Leica Biosystems


Source: PR Newswire